MAPT and early-onset autosomal dominant Alzheimer disease: Recently, the development of disease-modifying medicines has progressed even in the sector of dementia treatment domain, becoming increasingly important to detect pathogenic proteins, such as amyloid-β (Aβ) and phosphorylated tau protein (p-tau), for determining appropriate medications for patients with Alzheimer’s disease (AD).